An experimental therapy called CRMA-1001 is a remarkable development because, instead of targeting the virus directly, it silences the viral DNA; this is promising because current treatments rarely eliminate the DNA, which allows the virus to rebound
An experimental therapy called CRMA-1001 is a remarkable development because, instead of targeting the virus directly, it silences the viral DNA; this is promising because current treatments rarely eliminate the DNA, which allows the virus to rebound
<iframe src="https://hindustansphere.com/embed/cluster/750cacdb5ae1df31f8c60170b9323b471ed04d34" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Gene therapy offers to beat hepatitis B virus by muting its DNA"></iframe>
An experimental therapy called CRMA-1001 is a remarkable development because, instead of targeting the virus directly, it silences the viral DNA; this is promising because current treatments rarely eliminate the DNA, which allows the virus to rebound
